JP7615061B2 - 特発性肺線維症を治療する方法 - Google Patents

特発性肺線維症を治療する方法 Download PDF

Info

Publication number
JP7615061B2
JP7615061B2 JP2021576479A JP2021576479A JP7615061B2 JP 7615061 B2 JP7615061 B2 JP 7615061B2 JP 2021576479 A JP2021576479 A JP 2021576479A JP 2021576479 A JP2021576479 A JP 2021576479A JP 7615061 B2 JP7615061 B2 JP 7615061B2
Authority
JP
Japan
Prior art keywords
body weight
days
compound
administration
pharma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021576479A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022539329A5 (https=
JP2022539329A (ja
JPWO2020259528A5 (https=
Inventor
ヤンピン チャオ，
ホンジュン ワン，
ユアンユアン ジャン，
ウェイティン ゾン，
ジン チャオ，
ジン リ，
ウェイナ リウ，
リイン チョウ，
ヤンアン リウ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Tide Pharmaceutical Co Ltd
Original Assignee
Beijing Tide Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Tide Pharmaceutical Co Ltd filed Critical Beijing Tide Pharmaceutical Co Ltd
Publication of JP2022539329A publication Critical patent/JP2022539329A/ja
Publication of JP2022539329A5 publication Critical patent/JP2022539329A5/ja
Publication of JPWO2020259528A5 publication Critical patent/JPWO2020259528A5/ja
Application granted granted Critical
Publication of JP7615061B2 publication Critical patent/JP7615061B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/04—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021576479A 2019-06-25 2020-06-24 特発性肺線維症を治療する方法 Active JP7615061B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019092675 2019-06-25
CNPCT/CN2019/092675 2019-06-25
PCT/CN2020/097881 WO2020259528A1 (zh) 2019-06-25 2020-06-24 治疗特发性肺纤维化的方法

Publications (4)

Publication Number Publication Date
JP2022539329A JP2022539329A (ja) 2022-09-08
JP2022539329A5 JP2022539329A5 (https=) 2023-06-29
JPWO2020259528A5 JPWO2020259528A5 (https=) 2023-06-29
JP7615061B2 true JP7615061B2 (ja) 2025-01-16

Family

ID=74061495

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021576479A Active JP7615061B2 (ja) 2019-06-25 2020-06-24 特発性肺線維症を治療する方法

Country Status (11)

Country Link
US (1) US12582653B2 (https=)
EP (1) EP3992183A4 (https=)
JP (1) JP7615061B2 (https=)
KR (1) KR20220029681A (https=)
CN (2) CN114026072A (https=)
AU (1) AU2020305979B2 (https=)
BR (1) BR112021026214A2 (https=)
CA (1) CA3144113A1 (https=)
IL (1) IL289192A (https=)
TW (1) TWI804743B (https=)
WO (1) WO2020259528A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023539276A (ja) * 2020-08-31 2023-09-13 ベイジン タイド ファーマシューティカル カンパニー リミテッド Ｒｈｏ関連タンパク質キナーゼ阻害剤の塩、その固体形態、その調製方法およびその使用
CA3209240A1 (en) * 2021-02-22 2022-08-25 Samuel D. Waksal Rock2 inhibitor for the treatment of viral infection
NO346587B1 (en) * 2021-06-02 2022-10-17 Axichem Ab Capsaicin derivatives in the treatment of idiopathic pulmonary fibrosis
TW202327608A (zh) * 2021-09-17 2023-07-16 北京泰德製藥股份有限公司 治療病毒感染的方法
IL311447A (en) * 2021-09-18 2024-05-01 Beijing Tide Pharmaceutical Co Ltd A solid form of a Rho-linked protein kinase inhibitor or a solvate thereof, a method of preparation and use thereof
KR20240095429A (ko) * 2021-11-16 2024-06-25 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 Rock2 억제제의 나노결정 제제 및 이의 제조방법
WO2023134688A1 (zh) * 2022-01-13 2023-07-20 武汉朗来科技发展有限公司 一种rock抑制剂的盐及盐的晶型、组合物和药物用途
EP4591863A1 (en) * 2022-10-13 2025-07-30 Beijing Tide Pharmaceutical Co., Ltd. Method for treating pneumoconiosis
WO2025017499A1 (en) 2023-07-17 2025-01-23 Graviton Bioscience Bv Formulations and uses of rock2 inhibitors for als
IL325831A (en) 2023-07-17 2026-03-01 Graviton Bioscience Bv ROCK2 inhibitor formulations for central nervous system disorders
WO2025069008A1 (en) 2023-09-28 2025-04-03 Graviton Bioscience Bv Therapy for treating type 1 diabetes using rock2 and dyrk1 inhibitors
WO2025069009A1 (en) 2023-09-29 2025-04-03 Graviton Bioscience Bv Rock2 inhibitors in the treatment of obesity

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018506571A (ja) 2015-02-27 2018-03-08 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ Ｒｈｏ関連プロテインキナーゼの阻害及び疾患の治療のためのインダゾリルチアジアゾールアミン及び関連する化合物
US20180170939A1 (en) 2016-12-21 2018-06-21 CHIESI FARMACEUTISI S.p.A. Bicyclic dihydropyrimidine-carboxamide derivatives as rho- kinase inhibitors
WO2019001572A1 (zh) 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Rho 相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019000682A1 (zh) * 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018506571A (ja) 2015-02-27 2018-03-08 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ Ｒｈｏ関連プロテインキナーゼの阻害及び疾患の治療のためのインダゾリルチアジアゾールアミン及び関連する化合物
US20180170939A1 (en) 2016-12-21 2018-06-21 CHIESI FARMACEUTISI S.p.A. Bicyclic dihydropyrimidine-carboxamide derivatives as rho- kinase inhibitors
WO2019001572A1 (zh) 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Rho 相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途

Also Published As

Publication number Publication date
EP3992183A1 (en) 2022-05-04
US20220233538A1 (en) 2022-07-28
EP3992183A4 (en) 2023-06-21
TW202114679A (zh) 2021-04-16
KR20220029681A (ko) 2022-03-08
US12582653B2 (en) 2026-03-24
AU2020305979A1 (en) 2022-02-17
IL289192A (en) 2022-02-01
JP2022539329A (ja) 2022-09-08
CN114026072A (zh) 2022-02-08
AU2020305979B2 (en) 2026-04-23
WO2020259528A1 (zh) 2020-12-30
CA3144113A1 (en) 2020-12-30
CN119868365A (zh) 2025-04-25
TWI804743B (zh) 2023-06-11
BR112021026214A2 (pt) 2022-02-15

Similar Documents

Publication Publication Date Title
JP7615061B2 (ja) 特発性肺線維症を治療する方法
JP5883399B2 (ja) ｍＧｌｕＲ４アロステリック増強剤としてのピラゾロピリジン、ピラゾロピラジン、ピラゾロピリミジン、ピラゾロチオフェンおよびピラゾロチアゾール化合物、組成物、および神経機能不全を治療する方法
EP3932404A1 (en) Method for treating fatty liver disease and/or steatohepatitis
JP2019524747A (ja) 痛風または高尿酸血症に関連する症状を処置または予防するための化合物、組成物、および方法
JP7803924B2 (ja) 造血幹細胞移植によって引き起こされる移植片対宿主病を治療する方法
WO2024050434A1 (en) ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR MEDIATED DISEASES
JP7665529B2 (ja) ジアミノピリミジン化合物を使用することによって咳を治療する方法
HK40064686A (en) Method for treating idiopathic pulmonary fibrosis
WO2022135502A1 (zh) 多取代的尿嘧啶衍生物及其用途
EP4591863A1 (en) Method for treating pneumoconiosis
HK40063173A (en) Method for treating idiopathic pulmonary fibrosis
HK40121343A (zh) 治疗特发性肺纤维化的方法
JP2025529076A (ja) ＡｈＲ媒介疾患の治療に使用するタピナロおよびそのアナログ製剤
JP2024520758A (ja) Ｔｔｂｋ１の阻害剤
HK40086216A (en) Method for treating graft versus host disease caused by hematopoietic stem cell transplantation
HK40058942A (en) Method for treating fatty liver disease and/or steatohepatitis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220204

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20220204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230621

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230621

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241001

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241217

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241227

R150 Certificate of patent or registration of utility model

Ref document number: 7615061

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150